Your browser doesn't support javascript.
loading
Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease.
Panarese, Joseph D; Engers, Darren W; Wu, Yong-Jin; Bronson, Joanne J; Macor, John E; Chun, Aspen; Rodriguez, Alice L; Felts, Andrew S; Engers, Julie L; Loch, Matthew T; Emmitte, Kyle A; Castelhano, Arlindo L; Kates, Michael J; Nader, Michael A; Jones, Carrie K; Blobaum, Anna L; Conn, P Jeffrey; Niswender, Colleen M; Hopkins, Corey R; Lindsley, Craig W.
Afiliação
  • Panarese JD; Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Engers DW; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Wu YJ; Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Bronson JJ; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Macor JE; Bristol-Myers Squibb Co., Research & Development, 5 Research Parkway, Wallingford, Connecticut 06492 United States.
  • Chun A; Bristol-Myers Squibb Co., Research & Development, 5 Research Parkway, Wallingford, Connecticut 06492 United States.
  • Rodriguez AL; Bristol-Myers Squibb Co., Research & Development, 5 Research Parkway, Wallingford, Connecticut 06492 United States.
  • Felts AS; Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Engers JL; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Loch MT; Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Emmitte KA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Castelhano AL; Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Kates MJ; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Nader MA; Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Jones CK; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Blobaum AL; Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Conn PJ; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Niswender CM; Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Hopkins CR; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Lindsley CW; Davos Pharma, A Davos Chemical Company, 600 East Crescent Ave., Upper Saddle River, New Jersey 07458, United States.
ACS Med Chem Lett ; 10(3): 255-260, 2019 Mar 14.
Article em En | MEDLINE | ID: mdl-30891122
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: ACS Med Chem Lett Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: ACS Med Chem Lett Ano de publicação: 2019 Tipo de documento: Article